For decades, assessing a woman’s risk of hereditary cancer – particularly breast and ovarian cancer – involved a complex journey through the healthcare system. Referrals to genetic counselors, detailed family history reviews, and often lengthy waits were standard. But a shift is underway. Direct-access genetic testing is now available, allowing women to understand their risk without necessarily navigating the traditional specialist pathway. This increased accessibility raises important questions about who should consider testing, what the results signify, and how to interpret them responsibly.
The core of this change lies in the growing availability of clinically validated hereditary cancer genetic testing through private providers. While the National Health Service (NHS) offers genetic testing, eligibility is based on specific criteria outlined in NICE CG164 on familial breast cancer. These guidelines focus on the number and degree of affected relatives, and the types of cancer within a family. Many women, particularly those with smaller families or incomplete family histories, don’t meet these thresholds, leaving them without access to potentially life-saving information.
Understanding hereditary cancer risk is crucial as most breast and ovarian cancers develop sporadically. However, variants in genes like BRCA1, BRCA2, PALB2, and CHEK2 significantly elevate a woman’s lifetime risk. According to Cancer Research UK, a woman with a BRCA1 pathogenic variant faces a 70 to 80 percent lifetime risk of developing breast cancer, compared to approximately 12 percent in the general population. Identifying these variants allows for proactive measures, including intensified surveillance, risk-reducing interventions, and informed reproductive planning.
Who Benefits from Hereditary Cancer Testing?
Traditionally, the NHS prioritizes testing for women with a strong family history of breast or ovarian cancer, or those diagnosed at a young age. The NICE guidelines provide a structured framework for assessing risk, but they aren’t perfect. “There’s a significant population of women who fall into a gray area,” explains Dr. Sarah Klein, a clinical geneticist not affiliated with Jeen Health or Spital Clinic. “They may have a suspicion based on a single affected relative, or a family history that isn’t easily categorized. These are the women who are now benefiting from the increased access offered by direct-to-consumer testing.”
Private genetic testing removes the eligibility barriers, allowing any woman who wishes to understand her risk to do so. However, experts emphasize that the value of testing is greatest when there’s a clinical indication – a personal or family history that raises concern. It’s not a screening tool for the general population.
Key Genes to Consider
Several genes are associated with increased cancer risk. BRCA1 and BRCA2 remain the most well-known, with high penetrance – meaning a variant significantly increases the likelihood of developing cancer. However, other genes are increasingly recognized for their role in hereditary cancer syndromes:
- PALB2: A moderately high-risk gene for breast cancer, now frequently included in standard testing panels.
- CHEK2: Associated with a moderate increase in breast cancer risk.
- RAD51C and RAD51D: Linked to elevated ovarian cancer risk.
- MLH1, MSH2, MSH6, PMS2: These genes are associated with Lynch syndrome, which increases the risk of colorectal, endometrial, and ovarian cancers.
Comprehensive testing panels analyze multiple genes simultaneously, providing a more complete assessment of hereditary cancer risk.
How Does Testing Work?
Two primary options are available: at-home testing and in-clinic testing. Companies like Jeen Health offer at-home kits that utilize a saliva or cheek swab sample. The sample is sent to an accredited laboratory for analysis, and results are delivered digitally. This approach offers convenience and privacy, making it accessible to women who may face geographical or logistical barriers to in-person care.
In-clinic testing, offered by providers such as Spital Clinic, provides the benefit of a face-to-face consultation with a healthcare professional. This allows for immediate discussion of results, personalized risk assessment, and guidance on next steps. For women who receive a positive result, this consultation can be particularly valuable in navigating complex medical decisions.
The Importance of Genetic Counseling
Regardless of the testing method chosen, genetic counseling is a critical component of the process. Before testing, a counselor can help individuals understand which genes are most relevant to their family history, the implications of a positive or negative result, and the potential impact on family members. After testing, counseling provides the clinical context needed to interpret results accurately and develop a personalized management plan.
“A positive result doesn’t mean a cancer diagnosis is inevitable,” emphasizes Dr. Klein. “It means risk is elevated, and People can discuss strategies to mitigate that risk, such as enhanced surveillance, chemoprevention, or even preventive surgery.” A negative result, while reassuring, doesn’t eliminate risk entirely, as not all hereditary cancer genes are included in every panel.
What Happens After a Positive Result?
Women who test positive for a clinically significant variant are typically referred to a specialist genetics clinic for a comprehensive family assessment. Management options vary depending on the gene involved, the specific variant identified, and individual risk factors. These options may include annual MRI and mammography, risk-reducing medications like tamoxifen, or prophylactic surgery. For women considering pregnancy, genetic testing results can inform decisions about preimplantation genetic testing (PGT) and prenatal diagnosis.
The increasing accessibility of hereditary cancer testing represents a significant step forward in preventative healthcare. By empowering women with knowledge about their genetic risk, we can move towards a more proactive and personalized approach to cancer prevention and early detection.
As direct-to-consumer genetic testing becomes more widespread, ongoing research and education are crucial to ensure responsible utilize and accurate interpretation of results. The next step in improving access and outcomes will likely involve further refinement of testing panels, increased availability of genetic counseling services, and continued efforts to educate both healthcare providers and the public about the benefits and limitations of hereditary cancer testing.
Have questions about hereditary cancer testing? Share your thoughts in the comments below, and please share this article with anyone who might find it helpful.
